[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349016-105":59,"doc-detail-349016-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","characterization-of-the-d8p1c1-anti-adam17-inhibitory-monoclonal-antibody-and-generation-of-its-bispecific-t-cell-engager-derivative","Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative","","EGFR signaling, which relies on ADAM protease–mediated ligand shedding, supports progression of multiple cancers. The study characterizes D8P1C1, a fully human affinity-matured anti-ADAM17 monoclonal antibody, showing inhibition of EGFR ligand shedding and EGFR phosphorylation in cancer cell lines. In breast and ovarian xenografts, D8P1C1 reduced tumor growth with no discernible toxicity and demonstrated only modest activity in high-grade serous ovarian cancer. Radioimmuno PET confirmed tumor accumulation, and a D8P1C1-derived bispecific T-cell engager derivative showed improved in vitro anti-tumor efficacy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/characterization-of-the-d8p1c1-anti-adam17-inhibitory-monoclonal-antibody-and-generation-of-its-bispecific-t-cell-engager-derivative/349016/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/characterization-of-the-d8p1c1-anti-adam17-inhibitory-monoclonal-antibody-and-generation-of-its-bispecific-t-cell-engager-derivative/349016.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main mechanism by which D8P1C1 suppresses cancer signaling?","Question",{"text":113,"@type":114},"D8P1C1 inhibits ADAM17-dependent shedding of EGFR ligands, leading to reduced EGFR phosphorylation in cancer cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did D8P1C1 perform in breast versus ovarian cancer xenograft models?",{"text":118,"@type":114},"In xenograft assays, D8P1C1 showed stronger tumor growth inhibition in triple-negative breast cancer than in serous ovarian cancer models, with only modest efficacy in high-grade serous ovarian cancer and no discernible toxicity.",{"name":120,"@type":111,"acceptedAnswer":121},"How was D8P1C1 distribution in tumors evaluated?",{"text":122,"@type":114},"Radioimmuno PET imaging using 89Zr-DFO-D8P1C1 confirmed tumor accumulation of the antibody in both high-grade and non-high-grade serous ovarian tumor xenografts.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349016,1790198343,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article  \nCharacterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative  \nNayanendu Saha 1, Sang Gyu Lee 2, Elisa de Stanchina 3, Rachelle P. Mendoza 4,*, Darren R. Veach 2 and Dimitar B. Nikolov 1, *  \nAcademic Editor: Yong Teng  \nReceived: 6 February 2026  \nRevised: 17 March 2026  \nAccepted: 18 March 2026  \nPublished: 24 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; [sahan@mskcc.org](sahan@mskcc.org)  \n2 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n3 Antitumor Assessment Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n4 Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA  \n* Correspondence: [rpm2159@cumc.columbia.edu](rpm2159@cumc.columbia.edu) (R.P.M.); [nikolovd@mskcc.org](nikolovd@mskcc.org) (D.B.N.)  \nAbstract  \nEGFR signaling, which requires ligand shedding by ADAM proteases, drives the progression of a variety of cancers, including breast, ovarian and lung. We previously reported the generation and characterization of a fully human, affinity-matured anti-ADAM17 monoclonal antibody, D8P1C1, which inhibits both the proliferation of an array of cancer cell lines in vitro as well as breast cancer growth in a mouse xenograft model. Here, we show that the mAb inhibits the shedding of EGFR ligands and EGFR phosphorylation in cancer cell lines, thus explaining its anti-tumor effects. In a xenograft model with a high-grade serous ovarian cancer (HGSOC) cell line, D8P1C1 showed only modest therapeutic effect, without any discernible toxicity. These results suggest that ovarian cancers are less susceptible than breast cancers to therapeutic targeting of ADAM17-or EGFR-dependent signaling. Radioimmuno PET imaging with 89Zr-DFO-D8P1C1 confirmed tumoral accumulation of the mAb in high-grade and non-high-grade serous ovarian tumor xenografts. Furthermore, we report the generation and preliminary characterization of a bispecific T cell engager derivative of D8P1C1 with improved anti-tumor efficacy in vitro.  \nKeywords: ADAM17; bispecific T-cell engager; high-grade serous ovarian cancer; EGFR signaling  \n1. Introduction  \nThe human epidermal growth factor receptor (EGFR) family of tyrosine kinases is implicated in the development and proliferation of many human cancers, notably breast, lung, ovarian, prostate and colon [1]. Activation of EGFR signaling requires ligand shedding by ADAM17, and it has been documented that there is a strong correlation between high EGFR activation and high ADAM17 expression levels in cancer progression [2–5] . For instance, ADAM17-dependent EGFR ligand shedding was shown to be an important proliferative signal in triple-negative breast cancer (TNBC) [6] . Likewise, ADAM17 is upregulated in ovarian tumors and in turn activates EGFR signaling [7] . Because of the pivotal role of ADAM17 in the proteolytic shedding of cell-surface attached EGFR ligands, which triggers oncogenic signaling, targeted inhibition of ADAM17 is an efficient means of therapeutic intervention, particularly in solid tumors [8] .  \nADAMs are transmembrane proteins with an N-terminal pro-domain, followed by metalloprotease (MP), disintegrin (D), cysteine-rich (C), transmembrane and cytoplasmic domains [9] . ADAMs do not exhibit any typical substrate cleavage signature; rather, the specificity is inherent to interactions of the D + C domain region of the proteases with the substrates [10–13] . In addition, the ADAM metalloprotease domains display a high degree of sequence conservation, and, consequently, small-molecule inhibitors targeting the proteinase active site proved ineff","cbCaiqw4z182fK0k","https://ap.wps.com/l/cbCaiqw4z182fK0k","pdf",3066939,"English","# Introduction\n## ADAM17 inhibition and EGFR signaling rationale\n## Study background on D8P1C1 antibody\n# Results\n## Purification of the D8P1C1 mAb","[{\"question\":\"What is the main mechanism by which D8P1C1 suppresses cancer signaling?\",\"answer\":\"D8P1C1 inhibits ADAM17-dependent shedding of EGFR ligands, leading to reduced EGFR phosphorylation in cancer cells.\"},{\"question\":\"How did D8P1C1 perform in breast versus ovarian cancer xenograft models?\",\"answer\":\"In xenograft assays, D8P1C1 showed stronger tumor growth inhibition in triple-negative breast cancer than in serous ovarian cancer models, with only modest efficacy in high-grade serous ovarian cancer and no discernible toxicity.\"},{\"question\":\"How was D8P1C1 distribution in tumors evaluated?\",\"answer\":\"Radioimmuno PET imaging using 89Zr-DFO-D8P1C1 confirmed tumor accumulation of the antibody in both high-grade and non-high-grade serous ovarian tumor xenografts.\"}]","Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative | PDF",1790081219,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6eca87baac1d4794c0d345d968bc3af6.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10250d6a494721b0342e4cbfa8ccecc3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45622683a69e627ffa49633ee4737346.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db137161a76d8ce6d8efc36201824d44.webp",980,1385]